A phase II, single arm study of CarbopLatin plus Etoposide with Bevacizumab and Atezolizumab in patients with exTEnded-disease small-cell lung cancer (SCLC) &NDASH; CeLEBrATE trial

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 08 Dec 2023

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Carboplatin (Primary) ; Etoposide (Primary)
Indications Brain metastases; Liver metastases; Neuroendocrine carcinoma; Small cell lung cancer
Focus Therapeutic Use
Acronyms CeLEBrATE

24 Oct 2023 Results (n=51) assessing safety of Carboplatin, etoposide, bevacizumab, and atezolizumab in patients with extensive-stage SCLC presented at the 48th European Society for Medical Oncology Congress
12 Sep 2023 Results presented at the 24th World Conference on Lung Cancer.
05 Sep 2022 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com